Core Insights - Acuity (AYI) is expected to report quarterly earnings of $4.11 per share, reflecting a year-over-year increase of 10.2% [1] - Anticipated revenues for the quarter are projected to be $1.09 billion, representing an 8.7% increase compared to the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating analysts have reevaluated their initial estimates [1] Earnings Estimates and Revisions - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock [2] - Empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [2] Key Metrics Forecast - Analysts estimate 'Net Sales by Channel- Acuity Intelligent Spaces' will reach $249.73 million, indicating a 45.6% increase year-over-year [4] - 'Net Sales by Channel- Acuity Brands Lighting (ABL)- Total' is forecasted to be $851.82 million, suggesting a 1.3% year-over-year change [4] - 'Adjusted operating profit- Acuity Intelligent Spaces' is expected to be $52.56 million, up from $32.00 million reported in the same quarter last year [5] - 'Adjusted operating profit- Acuity Brands Lighting' is projected to reach $145.80 million, compared to $141.30 million reported in the same quarter last year [5] Stock Performance - Acuity shares have decreased by 10.6% over the past month, while the Zacks S&P 500 composite has moved down by 7.3% [5] - Acuity holds a Zacks Rank of 3 (Hold), indicating it is expected to mirror overall market performance in the near future [5]

Earnings Forecast - MSC Industrial (MSM) is predicted to report quarterly earnings of $0.84 per share, reflecting a 16.7% increase year-over-year [1] - Revenues are forecasted to be $934.27 million, representing a year-over-year increase of 4.8% [1] Earnings Estimate Revisions - The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days [2] - This revision indicates a collective reevaluation of initial estimates by analysts covering the stock [2] Importance of Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting potential investor actions regarding the stock [3] - Empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3] Key Metrics Projections - Analysts forecast 'Sales Days' to remain at 63, unchanged from the year-ago value [4] - 'Average Daily Sales (ADS)' is expected to reach $14.78 million, up from $14.20 million year-over-year [5] - 'Days Sales Outstanding' is projected at 41, compared to 36 in the same quarter of the previous year [5] Stock Performance - MSC Industrial shares have shown a return of -4.1% over the past month, compared to the Zacks S&P 500 composite's -6.2% change [5] - With a Zacks Rank 4 (Sell), MSM is expected to underperform the overall market in the near future [5]

Core Viewpoint - SELLAS Life Sciences Group, Inc. (SLS) has shown a significant price increase of 16.5% over the past four weeks, with a mean price target of $8.67 indicating a potential upside of 63.6% from the current price of $5.3 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $2.31, where the lowest estimate is $6.00 (13.2% increase) and the highest is $10.00 (88.7% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the price movement of SLS, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about SLS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 23.7% increase in the Zacks Consensus Estimate over the past month [11][12] - SLS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Assertio (ASRT) shares have increased by 16.3% in the past four weeks, closing at $14, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $39.59, representing a 182.8% upside [1] Price Targets and Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $7.79, where the lowest estimate of $28.00 indicates a 100% increase, and the most optimistic target is $45.00, suggesting a 221.4% increase [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ASRT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 110.7%, with one estimate moving higher and no negative revisions [12] - ASRT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] Caution on Price Targets - While consensus price targets are often sought after, their reliability as indicators of stock price direction is questionable, and investors should approach them with skepticism [3][10]

Core Viewpoint - Analysts expect Commercial Metals (CMC) to report quarterly earnings of $1.28 per share, reflecting a year-over-year increase of 392.3%, with revenues projected at $1.98 billion, up 13% from the previous year [1] Earnings Estimates - Prior to earnings announcements, revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock [2] - Trends in earnings estimate revisions have a strong correlation with short-term stock price performance [2] Revenue Projections - Analysts estimate 'Net Sales- Emerging Businesses Group- Net sales from external customers' to be $235.37 million, indicating a year-over-year change of +48.2% [4] - 'Net sales from external customers- North America' is projected at $1.50 billion, reflecting a year-over-year increase of +8.3% [4] - 'Net sales from external customers- Europe' is expected to reach $234.14 million, showing a year-over-year change of +18.2% [5] - 'Net sales from external customers- Corporate and Other' is forecasted at $10.78 million, with a year-over-year change of +1.3% [5] - The consensus estimate for 'Major product- North America- Other' stands at $50.82 million, indicating a change of +5.9% from the prior-year quarter [5] Pricing Metrics - The 'North America - Average selling price (per ton) - Raw materials' is expected to be $939.87, down from $956.00 in the same quarter last year [6] - 'Europe - Steel products metal margin per ton' is projected at $290.50, up from $275.00 in the previous year [6] - 'North America - Average selling price (per ton) - Downstream products' is forecasted at $1243.79, compared to $1221.00 in the same quarter last year [7] - 'North America - Average selling price (per ton) - Steel products' is expected to be $926.49, up from $814.00 in the previous year [7] - The 'North America - Average selling price (per ton) - Cost of ferrous scrap utilized per ton' is projected at $330.65, down from $338.00 in the same quarter last year [8] - The estimated 'North America - Average selling price (per ton) - Steel products metal margin per ton' is $595.84, compared to $476.00 a year ago [8] Shipping Metrics - Analysts suggest that 'Europe - Steel products (External tons shipped)' will likely reach 343.02 thousand, compared to 310.00 thousand in the previous year [9] Stock Performance - Over the past month, shares of Commercial Metals have returned -21.6%, while the Zacks S&P 500 composite has changed by -5.7% [10] - CMC currently holds a Zacks Rank 3 (Hold), indicating that its performance may align with the overall market in the near future [10]

Group 1 - Eton Pharmaceuticals, Inc. (ETON) closed at $20.77, with a 14% gain over the past four weeks, and a mean price target of $31 suggests a 49.3% upside potential [1] - The mean estimate includes three short-term price targets with a standard deviation of $5.57, where the lowest estimate of $26.00 indicates a 25.2% increase, and the highest estimate of $37.00 suggests a 78.1% increase [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 0.5% due to one upward revision over the last 30 days, with no negative revisions [12] - ETON holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Wall Street analysts expect Chewy (CHWY) to post quarterly earnings of $0.28 per share in its upcoming report, which indicates no change from the year-ago quarter. Revenues are expected to be $3.26 billion, up 0.3% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings annou ...

Core Viewpoint - H. B. Fuller (FUL) is expected to report quarterly earnings of $0.56 per share, reflecting a year-over-year increase of 3.7%, with revenues projected at $790.1 million, a slight increase of 0.2% compared to the previous year [1]. Earnings Estimates - There has been no revision in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts forecast 'Net Revenue- Hygiene, Health and Consumable Adhesives' to reach $364.87 million, a decrease of 0.9% from the prior-year quarter [5]. - The consensus for 'Net Revenue- Engineering Adhesives' is projected at $251.05 million, representing an increase of 6% from the previous year [5]. EBITDA Estimates - 'Adjusted EBITDA- Engineering Adhesives' is expected to be $47.65 million, up from $44.19 million reported in the same quarter last year [6]. - 'Adjusted EBITDA- Hygiene, Health and Consumable Adhesives' is projected at $48.19 million, compared to $46.89 million in the same quarter of the previous year [6]. Stock Performance - H. B. Fuller shares have declined by 22.9% over the past month, contrasting with a 3.6% decrease in the Zacks S&P 500 composite [6]. - The company holds a Zacks Rank of 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6].

Core Viewpoint - Stagwell (STGW) shares have increased by 28.1% in the past four weeks, closing at $6.07, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $8.11, representing a 33.6% upside [1]. Price Targets and Estimates - The average price target consists of seven short-term estimates ranging from a low of $6.50 to a high of $10.00, with a standard deviation of $1.14, indicating variability among analysts [2]. - The lowest estimate suggests a 7.1% increase from the current price, while the highest estimate indicates a potential upside of 64.7% [2]. Analyst Sentiment and Earnings Estimates - Analysts show strong agreement regarding Stagwell's ability to report better earnings than previously predicted, which supports the view of potential upside [4]. - There has been a positive trend in earnings estimate revisions, with one estimate moving higher in the last 30 days and no negative revisions, leading to a 2.6% increase in the Zacks Consensus Estimate for the current year [11][12]. Zacks Rank and Investment Potential - Stagwell currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13]. - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14].

Group 1 - Oruka Therapeutics, Inc. (ORKA) shares have increased by 29.6% in the past four weeks, closing at $41.75, with a mean price target of $59.08 indicating a potential upside of 41.5% [1] - The average of 13 short-term price targets ranges from a low of $40.00 to a high of $75.00, with a standard deviation of $12.34, suggesting variability in analyst estimates [2] - Analysts show strong agreement on ORKA's ability to report better earnings than previously predicted, which supports the expectation of an upside [4][11] Group 2 - The Zacks Consensus Estimate for ORKA's current year earnings has increased by 6.5% over the past month, with four estimates revised higher and no negative revisions [12] - ORKA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]